DNA barcoded peptide-MHC multimers to measure and monitor minor histocompatibility antigen-specific T cells after allogeneic stem cell transplantation
Authors:
- Kyra J FuchsKFKyra J Fuchs
- Marcus GöranssonMGMarcus Göransson
- Michel G D KesterMKMichel G D Kester
- Natasja W EttienneNENatasja W Ettienne
- Marian van de MeentMMMarian van de Meent
- Rob C M de JongRJRob C M de Jong
- Eva A S KosterEKEva A S Koster
- Constantijn J M HalkesCHConstantijn J M Halkes
- Ferenc ScheerenFSFerenc Scheeren
- Mirjam H M HeemskerkMHMirjam H M Heemskerk
- Peter van BalenPBPeter van Balen
- J H Frederik FalkenburgJFJ H Frederik Falkenburg
Open Access
- 9 December 2024
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 12 (12) , e009564
Abstract
Allogeneic stem cell transplantation (alloSCT) provides a curative treatment option for hematological malignancies. After HLA-matched alloSCT, donor-derived T cells recognize minor histocompatibility antigens (MiHAs), which are polymorphic peptides presented by HLA on patient cells. MiHAs are absent on donor cells due to genetic differences between patient and donor. T cells targeting broadly expressed MiHAs induce graft-versus-leukemia (GvL) reactivity as well as graft-versus-host disease (GvHD), while T cells for MiHAs with restricted or preferential expression on hematopoietic or non-hematopoietic cells may skew responses toward GvL or GvHD, respectively. Besides tissue expression, overall strength of GvL and GvHD is also determined by T-cell frequencies against MiHAs. Here, we explored the use of DNA barcode-labeled peptide-MHC multimers to detect and monitor antigen-specific T cells for the recently expanded repertoire of HLA-I-restricted MiHAs. In 16 patients who experienced an immune response after donor lymphocyte infusion, variable T-cell frequencies up to 30.5% of CD8+ T cells were measured for 49 MiHAs. High T-cell frequencies above 1% were measured in 12 patients for 19 MiHAs, with the majority directed against mismatched MiHAs, typically 6–8 weeks after donor lymphocyte infusion and at the onset of GvHD. The 12 patients included 9 of 10 patients with severe GvHD, 2 of 3 patients with limited GvHD and 1 of 3 patients without GvHD. In conclusion, we demonstrated that barcoded peptide-MHC multimers reliably detect and allow monitoring for MiHA-specific T cells during treatment to investigate the kinetics of immune responses and their impact on development of GvL and GvHD after HLA-matched alloSCT.Keywords
Funding Information
- EliteForsk researcher prize (N/A)
- KWF Kankerbestrijding (10713)
This publication has 50 references indexed in Scilit:
- Associations of minor histocompatibility antigens with outcomes following allogeneic hematopoietic cell transplantationAmerican Journal of Hematology, 2023
- Feasibility, safety, and efficacy of early prophylactic donor lymphocyte infusion after T cell-depleted allogeneic stem cell transplantation in acute leukemia patientsAnnals of Hematology, 2023
- Graft-versus-host disease is locally maintained in target tissues by resident progenitor-like T cellsImmunity, 2023
- Genetics of HLA Peptide Presentation and Impact on Outcomes in HLA-Matched Allogeneic Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2021
- Quantitative Assessment of T Cell Clonotypes in Human Acute Graft-versus-Host Disease TissuesTransplantation and Cellular Therapy, 2019
- Design and validation of conditional ligands for HLA‐B*08:01, HLA‐B*15:01, HLA‐B*35:01, and HLA‐B*44:05Cytometry Part A, 2015
- Mixed functional characteristics correlating with TCR‐ligand koff‐rate of MHC‐tetramer reactive T cells within the naive T‐cell repertoireEuropean Journal of Immunology, 2013
- Association of Disparities in Known Minor Histocompatibility Antigens with Relapse-Free Survival and Graft-versus-Host Disease after Allogeneic Stem Cell TransplantationTransplantation and Cellular Therapy, 2013
- Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramersJournal of Immunological Methods, 2009
- Confronting Complexity: Real-World Immunodominance in Antiviral CD8+ T Cell ResponsesImmunity, 2006